AWMSG medicines approvals
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): bedaquiline for pulmonary multidrug‑resistant tuberculosis in adult patients as part of an appropriate combination regimen; daclatasvir for chronic hepatitis C virus infection in adults with significant fibrosis or compensated cirrhosis (as part of combination treatment); defibrotide for severe hepatic veno-occlusive disease alongside haematopoietic stem-cell transplantation therapy (provided the approved patient access scheme is used); Triumeq (dolutegravir/abacavir/lamivudine) for treating human immunodeficiency virus infection in patients aged 12 years and over and weighing at least 40kg (provided the approved patient access scheme is used); entecavir for chronic hepatitis B virus infection in nucleoside-naive patients aged 2–18 years with compensated liver disease. See the AWMSG website for full details of restrictions.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068616
Recommended from Pharmaceutical Press